Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer ...
- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study explores Alpha DaRT combined with …